“In this therapy, we do not change or edit the genes that cause sickle cell disease,” Kanter says. “Instead, we use a viral vector to deliver a new gene that will make a healthy hemoglobin—a beta ...

It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.